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ABSTRACT  
Background 
Structural cortical networks (SCNs) reflect the covariance between the cortical 
thickness of different brain regions, which may share common functions and a common 
developmental evolution. SCNs appear abnormal in neurodegenerative conditions such 
as Alzheimer’s and Parkinson’s diseases, but have never been assessed in primary 
progressive multiple sclerosis (PPMS).  
Objective 
To test whether SCNs are abnormal in early PPMS and change over five years, and 
correlate with disability worsening.  
Methods 
Twenty-nine PPMS patients and 13 healthy controls underwent clinical and brain MRI 
assessments for five years. Baseline and five-year follow-up cortical thickness values 
were obtained and used to build correlation matrices, considered as weighted graphs to 
obtain network metrics. Bootstrap-based statistics assessed SCN differences between 
patients and controls and between patients with fast and slow progression.  
Results 
At baseline, patients showed features of lower connectivity (p=0.02) and efficiency 
(p<0.001) than controls. Over five years, patients, especially those with fastest clinical 
progression, showed significant changes suggesting an increase in network 
connectivity (p<0.001) and efficiency (p<0.02), not observed in controls.  
 
Conclusion 
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SCNs are abnormal in early PPMS. Longitudinal SCN changes demonstrated a switch 
from low- to high-efficiency networks especially among fast progressors, indicating 
their clinical relevance.  
 
194/200 
 
Key words: Primary progressive multiple sclerosis, structural covariance networks, 
cortical thickness, grey matter damage, robust statistical methods, bootstrapping.  
 
 
  
 5 
INTRODUCTION  
In primary progressive multiple sclerosis (PPMS), grey matter (GM) damage occurs 
from the earliest stages of the condition1-4 and is associated with greater risk of 
disability accumulation.1-3 Whole brain GM volume loss is commonly used as marker 
of GM damage in PPMS.5 However, the strength of the correlation between GM 
damage and clinical deterioration in PPMS is only moderate. A possible explanation 
for that could be that the techniques used to assess GM volume loss are frequently based 
on averaged values over the whole brain, failing to capture the spatial variability of GM 
volume loss. Instead, innovative approaches such as covariance network analysis 
applied to cortical thickness data can account for the complexity of the spatial 
distribution of such GM damage, providing new insights into the pathogenic 
mechanisms underlying disability progression.6   
 
Covariance networks allow the assessment of the interdependencies across variables of 
a system –generally a biological system, e.g. the brain GM volume– on a specific 
outcome. Moreover, they do so in a straightforward fashion, through the use of graph 
theory principles. In the brain, covariance networks have been successfully applied to 
cortical thickness data, where they are called structural cortical networks (SCNs).7 
SCNs are based on the covariance of GM thickness of different regions, being therefore 
able to capture important aspects of the spatial complexity of GM data. SCNs use the 
correlations between the GM thickness of the different areas as the main predictors of 
the clinical outcome and can potentially provide complementary information to more 
conventional analysis methods of structural data. Additionally, it has been shown that 
cortical areas with similar thickness or volumes share common functions and a common 
developmental evolution.7  
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In the healthy brain, SCNs have proved to behave as small-world networks, where 
transmission of information across the nodes of the network is done fast and efficiently 
thanks to a particularly small mean length of the shortest path, also known as mean 
shortest path,6, 8 an estimate of the shortest distance between any pair of nodes in the 
network.9 Thus, healthy SCNs can be considered as high efficiency networks. In 
neurodegenerative conditions such as MS, SCNs show disruptive patterns early in the 
disease course,10-13 leading to suboptimal topological organisations.14, 15 However, the 
behaviour of SCNs in progressive MS has never been assessed.  
 
Here we tested the hypotheses that there are abnormalities in SCNs in PPMS patients 
when compared with controls and that the main characteristics of the SCNs, such as 
mean shortest path, local and global efficiency and nodal connectivity, significantly 
change over five years of follow-up. To understand whether SCNs changes reflect 
mechanisms that contribute to disability, the differences in SCNs characteristics 
between patients who showed a rapid worsening of disability and those who showed a 
slow worsening of disability were investigated.  
 
METHODS 
Subjects  
All subjects included in this study belong to a prospectively followed-up cohort of 44 
patients with a diagnosis of early PPMS (i.e. and less than five years from symptom 
onset) and 20 healthy controls (HCs). The clinical and demographic features of this 
cohort have been previously reported.1, 16-18 Because of the nature of this study, where 
covariance networks were obtained with cortical thickness values and where such 
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networks had to have the same size at baseline and at follow-up to be comparable, we 
excluded 15 patients and seven HCs who had missed two or three time points. Patients 
with only one time point missing were included and the missing value was imputed 
using simple linear regression, as explained below.  
   
All patients were clinically assessed using the Expanded Disability Status Scale 
(EDSS)19 at baseline, and at 12, 24, 36 and 60 months, as reported elsewhere.1, 16-18 An 
EDSS increase over the five-year follow-up period greater than 0.2 points/year (which 
was the median in the whole PPMS group) was considered as fast progression. We also 
included a group of healthy controls (HCs). All participants underwent MRI scans at 
all time points.  
 
The study was approved by the local Ethics Committee and all participants provided 
informed written consent. 
 
MRI analysis 
All MRI scans were performed with a 1.5 T GE Signa Echospeed MRI (Milwaukee, 
WI) scanner. The scanner maximum gradient strength was 33 mT m-1.  
 
Acquisition of brain structural scans 
For all subjects and for the purpose of this study, the following images at baseline and 
five-year follow-up were analysed: axial oblique, proton-density (PD), dual echo, fast 
spin echo images were acquired, as previously described;1, 16-18 axial three-dimensional 
fast prepared spoiled gradient recall (3D-FSPGR, 3D T1-weighted) (resolution: 
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1.71.71.5mm3). In April 2004 there was a scanner upgrade, which was taken into 
account in all subsequent analyses (see statistical analysis section).  
 
We manually outlined T2 hyperintense WM lesions on the PD-weighted images using 
the semi-automated edge finding tool in JIM (JIM v6.0, Xinapse systems, Aldwincle, 
UK, http://www.xinapse.com). We co-registered PD-weighted lesion masks to the 3D-
T1 images using a pseudo-T1 image generated by subtracting the PD from the T2-
weighted image.20 We transformed lesion masks from native space to 3DT1 space and 
the 3DT1 images were filled using a non-local patch match lesion filling technique.21  
 
Measurement of cortical thickness  
We calculated cortical thicknesses for 68 bilateral brain cortical areas using the 
FreeSurfer version 5.3 longitudinal stream.22-24 Briefly, this included skull-stripping, 
intensity normalisation, non-linear registration to Talairach space, segmentation, 
estimation of brain surfaces, and surface parcellation. We visually assessed the final 
segmentation, and re-ran the pipeline after manual correction in cases of incorrect 
surface estimation. We performed an unbiased longitudinal image analysis creating a 
symmetric within-subject template.25 Afterwards, in order to increase reliability and 
statistical power all the steps were re-initialised for each time point using the common 
information.22 We extracted cortical thickness values for each cortical parcellation 
according to Desikan-Killiany atlas.24 
 
Structural covariance network analysis 
Construction of weighted structural covariance networks 
We built SCNs for all subjects, at baseline and five-year follow-up, as follows:  
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1) Networks were built using the same number of subjects at both time points. Thus, 
any missing values in cortical thickness data at five-year follow-up were imputed, for 
each subject, applying a single imputation technique that used simple linear regression, 
where the values at the remaining time points were used to estimate the slope and hence 
the missing point. To minimise the introduction of bias, such single imputation 
technique was only applied if patients had missed, at most, one visit.   
2) Any variability in the cortical thickness data related to lesion load, age or gender, for 
all subjects and time points, was removed regressing at once cortical thickness data 
over lesion load at baseline, mean cortical thickness at baseline, age and gender. 
Additionally, a variable indicating whether the images had been acquired before or after 
the upgrade (April 2004) was also included as a covariate. Controls were assigned a 
lesion load equal to zero mL, as previously done.13, 26 In subsequent steps, we used the 
residuals of these regression models as the new, adjusted, cortical thickness values.7  
3) For each group and time point, i.e. all PPMS patients, HCs, PPMS patients with fast 
disability worsening and PPMS with slow worsening, at baseline and five-year follow-
up, pairwise Pearson’s correlation matrices using adjusted cortical thickness values 
were obtained using MATLAB (The MathWorks, Inc., Natick, Massachusetts, USA).  
4) We obtained correlation matrices with the absolute value of Pearson’s correlation 
coefficients, which corresponded to weighted networks that reflected the strength of the 
association regardless of its sign.7  
 
Obtaining network topological metrics 
Each weighted matrix was considered as the numerical representation of a network with 
68 nodes (i.e. 68 cortical areas) and edges that indicated the strength of the connection 
between two cortical areas. Thus, we obtained network topological metrics for each 
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network, i.e. for each group and time point, using the freely available Brain 
Connectivity Toolbox9 (https://sites.google.com/site/bctnet/) in MATLAB (The 
MathWorks, Inc., Natick, Massachusetts, USA). These metrics were:  
1. Mean nodal strength, the average, across all nodes, of the nodal strength, defined as 
the sum of the correlation coefficients of the edges emerging from a given node. A node 
with a high strength indicates that the node is very well connected and a network with 
high mean nodal strength indicates a very well connected network. In this context, 
highly connected networks indicate a high degree of similarity across cortical regions.   
2. Nodal clustering coefficient, which reflects the connectivity among the neighbours 
of a given node and can be understood as the probability that each two nodes that are 
connected to a given node are also connected among themselves. Therefore, the mean 
clustering coefficient is the average clustering coefficient across all nodes of the 
network.27 In this context, a network with a high mean clustering coefficient would 
indicate that cortical regions have, in general, strong similarities regarding cortical 
thickness with neighbouring regions (in the network).  
3. Mean shortest path (or characteristic path length, L), the average of the shortest path 
lengths between all pairs of nodes in the network.9 Smaller values of mean shortest path 
infer more efficient information transfer between nodes and greater information 
integration within the network.28  
4. Global efficiency, the reciprocal of the harmonic mean of the shortest path lengths of 
the entire network.28  
5. Local efficiency, the reciprocal of the harmonic mean of the shortest path lengths of 
the subgraph (i.e. subnetwork) defined by the neighbours of a given node.28 Mean local 
efficiency is the across-node average of local efficiency values of the nodes of the 
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network.9 Higher global and local efficiency values indicate greater ability to integrate 
information, globally and locally, respectively.  
6. Modularity coefficient, which describes how well a network can be subdivided into 
groups of nodes (i.e. modules) highly correlated with each other.   
  
Statistical analysis  
Descriptive and structural imaging data analyses 
We report descriptive statistics as mean (standard deviation [SD]) or median (range), 
depending on the nature of the variable. Changes in mean cortical thickness over five 
years were assessed using linear mixed-effects models. The dependent variable was 
‘cortical thickness’ and the main explanatory variables were ‘time’, a ‘categorical group 
indicator’: patient/control, and an interaction term: ‘time X group indicator’, which 
assessed differences in the rates of change in cortical thickness between groups. All 
models were adjusted for age, gender, lesion load at baseline (HCs were assigned lesion 
load equal to zero) and upgrade status (i.e. before or after the scanner upgrade). In 
patients only, changes in lesion load over five years were assessed using similar linear 
mixed-effects models. The dependent variable was ‘lesion load’ and the main 
explanatory variable was ‘time’. When patients with fast and slow progression were 
compared, an interaction term: ‘time X group indicator’ was also included as a 
covariate. Mixed-effects models allowed for three hierarchical levels: cortical thickness 
measurements at each time point, cortical area and subject. These models were run 
using all available data: baseline, 12, 24, 36 and 60 months, as explained in the 
Supplementary methods. All the above described statistical analyses were carried out 
with Stata 14.2 (Copyright 1985-2015 StataCorp LLC). 
 
 12 
SCN analysis in all PPMS patients and HCs 
Given that all network parameters were obtained at the network level, i.e. we had a 
value for each network, classical statistical approaches could not be used to compute 
the 95% confidence intervals (95% CI) of the metric values at baseline and their 
changes over time. We used, instead, a bootstrap-based approach which has been 
previously applied13 and is described in detail in the Supplementary methods.  
 
SCN analysis in PPMS patients with fast and slow progression 
The same steps described above were also applied to assess the 95% CIs of baseline, 
follow-up and change values for the network metrics in the groups of PPMS patients 
with fast and with slow progression.  
 
Data availability  
The models and data sets that have been generated during the current study are 
available, on reasonable request, from the corresponding author. 
 
RESULTS 
For this study, we included 29 patients (11 female) and 13 healthy controls (HCs). 
During the five-year follow-up, 13 patients were classified as showing fast disability 
progression and the remaining 16 slow progression. Patients had a greater decrease in 
cortical thickness over time than HCs (p<0.001), whereas no differences were seen 
between fast and slow progressors (Table 1).  
 
Structural cortical network analysis 
All PPMS patients vs HCs 
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At baseline, patients showed lower mean nodal strength (p=0.02) and longer mean 
shortest path (p<0.001) of their SCNs when compared to controls (Table 2; Figure 1). 
No differences were observed in other network metrics.  
 
During the five years of follow-up, patients showed a significantly greater decrease in 
mean shortest path, denoting a more efficient network, than HCs (p=0.03). Patients also 
showed a significant increase in mean nodal strength (p<0.001) and mean clustering 
coefficient (p=0.01), which was not observed in HCs (Table 3; Figure 2).  
 
When analysing regional changes in metrics that admit a node-level analysis, i.e. 
clustering coefficient and local efficiency, the most prominent changes in the SCN of 
patients with PPMS appeared in the post- and pre-central gyri and the entorhinal cortex. 
This regional pattern was not clearly observed in HCs’ network (Figure 3).  
 
PPMS  patients with fast vs slow progression 
At baseline, fast progressors showed a significantly shorter mean shortest path than 
slow progressors: 3.14 vs. 3.63 (p=0.04), indicating higher network efficiency (Table 
4; Figure 4).  
 
Over the five-year follow-up period, fast progressors showed a significant increase in 
mean nodal strength and mean clustering coefficient (p=0.02 and p=0.03, respectively), 
whereas slow progressors only showed changes in the nodal strength. Yet the 
differences between patient groups in the rates of change in these metrics did not reach 
statistical significance. Fast progressors also showed significant changes in all nodal 
distance metrics indicating a progressive increase in network efficiency over time: 
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mean shortest path decreased (p<0.001) and global and local efficiency increased 
(p=0.02 for both). Slow progressors, instead, only showed a decrease in mean shortest 
path (p=0.01) (Table 5; Figure 5).  
 
A visual inspection of the changes in the SCN parameters that admit a node-level 
analysis, the most prominent changes in fast progressors mirrored the regional pattern 
of changes observed in the whole PPMS cohort. Instead, changes in slow progressors 
did not show any clear regional predominance (Figure 3).  
 
DISCUSSION 
In this longitudinal study, we describe, for the first time, the dynamics of SCNs in 
progressive MS. Our finding of an overall lower connectivity and efficiency of the 
patients’ network as compared to the controls’ network is in line with previous studies, 
which showed that cortical networks were disrupted in established MS.10, 11, 15 In our 
study, as in He et al.’s study, we used cortical thickness data adjusted for lesion load 
and mean cortical thickness at baseline. Thus, although possible confounding effects 
derived from early brain damage had already been removed before obtaining our 
correlation matrices, we could still see a less efficient network in patients than in 
controls. As pointed out by He et al. (2009), these findings reflect a disrupted 
harmonisation of cortical thickness among brain cortical regions in our patients. 
Interestingly, neither at baseline nor at follow-up did patients and controls significantly 
differ in terms of mean cortical thickness. This means that SCN analysis is likely to 
have detected morphological changes not seen using conventional mean-based cortical 
thickness metrics.15  
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When temporal network dynamics were analysed, all patients’ networks showed a 
significant increase in both connectivity and efficiency metrics, which was not observed 
in the controls’ network. This phenomenon was also –and especially– observed in the 
network of patients with the fastest progression, whereas slow progressors’ network 
only showed minimal changes. Importantly, the hints of different behaviour between 
fast and slow progressors happened in the absence of significant differences between 
groups in the rates of change in cortical thickness over time, highlighting the fact that 
cortical thickness and cortical network analyses provide at least partly independent 
pieces of information. Additionally, when patients with fast and slow progression were 
compared, the fast progressors’ network showed overall higher connectivity and 
efficiency values than the slow progressors’ network at both baseline and five-year 
follow-up, in line with the observed longitudinal changes. However, this finding would 
be in apparent contradiction with the overall lower connectivity and efficiency of 
patients’ network when compared to the controls’ one and suggests a biphasic 
behaviour of the SCNs in patients: an initial efficiency loss would be followed by a 
gain in efficiency. Thus, whereas the initial stages of cortical atrophy may cause the 
initial disorganisation among cortical thickness of different brain regions leading to a 
less efficient network, the latest stages of atrophy may imply increasing 
homogenisation of cortical thickness across areas, leading to increased cortical network 
connectivity and efficiency.  
 
Longitudinal changes observed in network topological properties in patients could be 
considered as network fingerprints in progressive MS. These changes describe a 
shortening of the mean shortest paths in the whole network and the local subnetworks 
formed of each cortical area and its neighbouring areas. Neighbourhood in the context 
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of SCNs is determined by the presence of a statistical correlation between the cortical 
thickness of each pair of areas. Therefore, an increase in local efficiency would reflect 
an increased correlation among the cortical thickness of those areas that were already 
highly correlated. Conversely an increase in global efficiency would reflect a general 
strengthening in the correlations between the cortical thickness of each pair of areas, 
independently of whether they had already shown a high correlation or not, in line with 
the observed increase in network connectivity. Whether these changes are supporting a 
preservation of function or are actually maladaptive is a challenging question that is 
still unresolved in the context of connectivity analysis. 
 
In our study, the increase in connectivity and local efficiency did not occur 
homogeneously throughout the whole brain. It mainly occurred in the post- and pre-
central gyri, the sites for primary sensory and motor cortices, respectively, and also the 
entorhinal cortex, a medial temporal region largely involved in memory networks, as 
shown in Figure 3. Therefore, it could be possible that the clinical relevance of such 
abnormal cortical network changes was in fact related to the location of the regional 
changes in network connectivity. Damage in these regions has been repeatedly 
observed in neurodegenerative conditions.29, 30 A recent post-mortem study showed 
extensive fibrinogen deposition in the motor cortex of people with progressive MS, 
which was not present in the healthy control cortex and which correlated with the 
degree of neurodegeneration.30 Moreover, these regions have also been considered as 
hubs, i.e. highly connected areas or nodes, in networks defined through diffusion-
weighted MRI techniques.31 Therefore, they may be especially vulnerable to damage 
in neurodegenerative conditions.  
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Our study has some limitations, in particular  the relatively small sample size, especially 
in the control group. On the other hand, the homogeneity of this unique cohort, i.e. 
PPMS patients evaluated within five years of disease onset, the long follow-up and our 
robust statistical approach offset the impact of the small sample size. Yet our statistical 
approach was not primarily designed to address the problem of small sample size but 
to ensure unbiased statistical inferences, given the group-level nature of network 
metrics. The small sample size in the control group might have contributed to the lack 
of significant changes over time in controls. However, the size of the healthy control 
group was similar to the size of both patient groups, i.e. those with fast and with slow 
progression, and the fast progressors did show significant changes over time despite the 
small numbers. Thus, it is unlikely that the smaller size of the control group was 
responsible for the lack of significant changes over time observed in this group. 
Nonetheless, future studies with larger cohorts are necessary to confirm our findings. 
 
Another potential limitation is that possible confounders were not always equally 
distributed across groups. Although we built our SCNs using cortical thickness values 
adjusting for covariates, it might be possible that some confounding effect of these 
variables remained after the adjustment. Additionally, to predict the missing cortical 
thickness values we assumed that cortical thickness dynamics over time varied in a 
linear fashion and the presence of non-linear behaviours of our cortical thickness values 
over time were not explored, given the relatively small sample size of our cohort. Future 
studies with larger cohorts using more complex models to impute missing cortical 
thickness data and to further minimise the effect of potential confounders are warranted.  
 
 18 
Finally, in our study we did not include deep GM regions to compute our networks. 
Nonetheless, it is possible that deep GM plays a major role in the complex biological 
system defined by the brain GM, especially in MS patients,2 and its inclusion in future 
SCN studies in progressive MS should be considered.  
 
In conclusion, we present results of the first longitudinal cortical network analysis in 
primary progressive MS, revealing aspects of cortical atrophy dynamics beyond data  
obtained from the conventional analysis of cortical thickness. In particular, we found 
lower connectivity and efficiency in PPMS patients’ networks as compared to controls. 
For the first time we demonstrate an increase in connectivity and efficiency in patients 
with progressive MS over time, suggesting that SCN dynamics may have a biphasic 
behaviour. These changes, which were not observed in healthy controls, were driven 
by changes in patients with faster clinical deterioration over time, possibly reflecting 
their clinical relevance.  
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Table 1. Demographic, clinical and neuroimaging data at baseline and over time 
Variable All PPMS 
N=29 
Healthy 
controls 
N=13 
PPMS 
vs HCs, 
p-value 
(*) 
PPMS with 
fast 
progression 
N=13 
PPMS with 
slow 
progression 
N=16 
Fast vs slow 
progressors, 
p-value (*) 
Demographic data 
Age at 
study 
onset 
[years], 
mean 
(SD) 
46.241 
(10.077) 
34.083 
(6.640) 
p<0.001 
43.462 
(0.445) 
48.5  
(9.494) 
p=0.1853 
Gender, 
no. 
females 
(%) 
11 (38%) 5 (38%) p=0.823 5 (38%) 6 (38%) p=0.958 
EDSS score 
Baseline 
score, 
median 
(range) 
4.0 
(3.5 to 6.5) 
- - 
4.0 
(3.5 to 6.5) 
4.0 
(3.5 to 6.5) 
p=0.862 
five-year 
score, 
median 
(range) 
6.25 
(2.0 to 8.0) 
- - 
6.5 
(5.5 to 8.0) 
4.0 
(2.0 to 7.0) 
p<0.001 
Yearly 
rate of 
change 
(95% CI), 
p-value 
0.221 (0.121 
to 0.320), 
p<0.001 
- - 
0.438 
(0.329 to 
0.547), 
p<0.001 
0.048 
(-0.047 to 
0.144), 
p=0.324 
p<0.001 
Cortical thickness [mm] 
Baseline 
mean 
(SD)  
2.549  
(0.189) 
2.514 
(0.125) 
p=0.517 
2.543  
(0.157) 
2.553  
(0.159) 
p=0.820 
five-year 
mean 
(SD)  
2.500  
(0.190) 
2.504 
(0.126) 
p=0.940 
2.489  
(0.158) 
2.499  
(0.160) 
p=0.821 
Yearly 
rate of 
change 
(95% CI), 
p-value  
-0.010 
(-0.012 to -
0.008), 
p<0.001 
-0.002 
(-0.005 to 
0.0004), 
p=0.102 
p<0.001 
-0.011  
(-0.013 to -
0.008), 
p<0.001 
-0.011  
(-0.013 to 
-0.009), 
p<0.001 
p=0.994 
T2 lesion volume [mL] 
Baseline 
mean 
(SD) 
20.114 
(15.948) 
- - 
18.597 
(17.911) 
19.549 
(20.155) 
p=0.889 
five-year 
mean 
(SD) 
35.475 
(35.019) 
- - 
45.186 
(31.299) 
22.403 
(32.519) 
p=0.025 
Yearly 
rate of 
change 
(95% CI), 
p-value 
2.533 (0.563 
to 4.503), 
p=0.012 
- - 
5.318 
(2.241 to 
8.395), 
p=0.001 
0.571(-2.213 
to 3.354), 
p=0.688 
p=0.006 
 
Table 1 (footnote). (*) Adjusted for age, gender and lesion load at baseline. Abbreviations: CI: 
confidence interval; EDSS: Expanded Disability Status Scale; HCs: healthy controls; N: number of 
subjects; PPMS: primary progressive multiple sclerosis; SD: standard deviation.    
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Table 2. Estimated baseline and five-year follow-up values of network 
parameters in PPMS patients and controls  
 
 
Table 2 (footnote). Comparison between PPMS patients and HCs was made looking at the 95% CIs. 
Significant p-values are indicated in bold. Abbreviations: CI: confidence interval; HCs: healthy controls; 
PPMS: primary progressive multiple sclerosis.   
 
  
 PPMS patients (all) HCs 
Patients vs HCs, 
estimated p-value  
1. Measures of nodal connectivity  
Mean nodal strength, estimated value (bootstrap-based 95% CI)  
Baseline  
Follow-up  
11.642 (10.087 to 13.832) 
17.757 (13.819 to 22.199) 
16.741 (13.255 to 21.421) 
21.122 (17.106 to 28.412) 
0.02 
0.40 
Mean clustering coefficient, estimated value (bootstrap-based 95% CI)  
Baseline  
Follow-up  
0.1798 (0.156 to 0.210) 
0.2482 (0.205 to 0.304) 
0.221 (0.178 to 0.282) 
0.282 (0.232 to 0.388) 
0.20 
0.50 
 
2.  Measures of nodal distance 
 
Mean shortest path, estimated value (bootstrap-based 95% CI)  
Baseline  
Follow-up  
4.554 (4.192 to 4.893) 
3.495 (3.129 to 3.938) 
3.2828 (2.951 to 3.625) 
2.8596 (2.482 to 3.169) 
<0.001 
0.02 
Global efficiency, estimated value (bootstrap-based 95% CI)  
Baseline  
Follow-up  
0.309 (0.274 to 0.345) 
0.369 (0.330 to 0.414) 
0.3596 (0.314 to 0.414) 
0.4093 (0.364 to 0.491) 
0.10 
0.25 
Mean local efficiency, estimated value (bootstrap-based 95% CI)  
Baseline  
Follow-up  
0.213 (0.187 to 0.245) 
0.278 (0.237 to 0.331) 
0.2566 (0.214 to 0.315) 
0.3151 (0.266 to 0.413) 
0.20 
0.40 
 
3.  Measures of network organisation 
 
Modularity coefficient (bootstrap-based 95% CI)  
Baseline 
Follow-up 
0.095 (0.082 to 0.111) 
0.098 (0.073 to 0.118) 
0.097 (0.082 to 0.119) 
0.100 (0.072 to 0.123) 
0.90 
0.90 
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Table 3. Five-year changes in SCN parameters, in PPMS patients and HCs 
 
 
Table 3 (footnote). Comparison between PPMS patients and HCs was made looking at the 95% CIs. 
Significant p-values are indicated in bold. Abbreviations: CI: confidence interval; HCs: healthy controls; 
PPMS: primary progressive multiple sclerosis 
 
  
 PPMS patients (all) HCs 
Patients vs HCs, 
estimated p-value  
1. Measures of nodal connectivity  
Mean nodal strength, estimated value (bootstrap-based 95% CI), p-
value 
 
Estimated 
change  
6.116 (1.938 to 9.847), 
p<0.001 
4.381 (-0.075 to 10.450),  
p=0.06 
0.70 
Mean clustering coefficient, estimated value (bootstrap-based 95% CI), 
p-value 
 
Estimated 
change  
0.0684 (0.020 to 0.125), 
p=0.01 
0.061 (-0.003 to 0.153),  
p=0.06 
0.90 
 
2.  Measures of nodal distance 
 
Mean shortest path, estimated value (bootstrap-based 95% CI), p-value  
Estimated 
change  
-1.059 (-1.431 to -
0.578), p<0.001 
-0.423 (-0.754 to -0.149) 
p<0.001 
0.03 
Global efficiency, estimated value (bootstrap-based 95% CI), p-value  
Estimated 
change  
0.060 (0.011 to 0.115), 
p=0.02 
0.050 (-0.006 to 0.121), 
p=0.10 
0.90 
Mean local efficiency, estimated value (bootstrap-based 95% CI), p-
value 
 
Estimated 
change  
0.066 (0.018 to 0.119), 
p=0.01 
0.058 (-0.003 to 0.144),  
p=0.07 
0.90 
 
3.  Measure of network organisation 
 
Modularity coefficient (bootstrap-based 95% CI), p-value  
Estimated 
change  
0.002 (-0.024 to 0.025), 
p=0.90 
0.002 (-0.039 to 0.027),  
p=0.95 
>0.99 
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Table 4. Estimated baseline and five-year follow-up values of SCN parameters in 
PPMS patients with fast and slow progression  
 
 
 
Table 4 (footnote). Significant p-values are indicated in bold. Abbreviations: CI: confidence interval; 
PPMS: primary progressive multiple sclerosis.  
 
  
 
Patients with fast 
progression 
Patients with slow  
progression 
Patients with fast vs slow 
progression, estimated p-
value  
1. Measures of nodal connectivity  
Mean nodal strength, estimated value (bootstrap-based 95% CI)  
Baseline  
Follow-
up  
17.831 (14.869 to 22.819) 
24.586 (18.892 to 32.238) 
15.076 (12.480 to 18.933) 
17.977 (14.741 to 23.207) 
0.30 
0.10 
Mean clustering coefficient, estimated value (bootstrap-based 
95% CI) 
 
Baseline  
Follow-
up  
0.234 (0.195 to 0.299) 
0.327 (0.251 to 0.440) 
0.234 (0.207 to 0.278) 
0.243 (0.208 to 0.309) 
>0.99 
0.20 
 
2.  Measures of nodal distance 
 
Mean shortest path, estimated value (bootstrap-based 95% CI)  
Baseline  
Follow-
up  
3.136 (2.803 to 3.418) 
2.588 (2.230 to 2.951) 
3.631 (3.275 to 3.989) 
3.2589 (2.890 to 3.598) 
0.04 
0.02 
Global efficiency, estimated value (bootstrap-based 95% CI)  
Baseline  
Follow-
up  
0.372 (0.331 to 0.428) 
0.451 (0.388 to 0.542) 
0.384 (0.352 to 0.425) 
0.381 (0.344 to 0.436) 
0.70 
0.20 
Mean local efficiency, estimated value (bootstrap-based 95% CI)  
Baseline  
Follow-
up  
0.270 (0.230 to 0.333) 
0.359 (0.287 to 0.466) 
0.273 (0.245 to 0.317) 
0.278 (0.243 to 0.341) 
0.99 
0.10 
 
3.  Measures of network organisation 
 
Modularity coefficient, estimated value  (bootstrap-based 95% 
CI) 
 
Baseline 
Follow-
up 
0.091 (0.075 to 0.112) 
0.084 (0.052 to 0.108) 
0.092 (0.077 to 0.110) 
0.110 (0.092 to 0.128) 
0.99 
0.10 
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Table 5. Five-year changes in SCN parameters, in PPMS patients with fast and 
slow progression  
 
 
 
Table 5 (footnote). Significant p-values are indicated in bold. Abbreviations: CI: confidence interval; 
HCs: healthy controls; PPMS: primary progressive multiple sclerosis.   
 
 
  
 
Patients with fast 
progression 
Patients with slow  
progression 
Patients with fast vs slow 
progression, estimated p-value  
1. Measures of nodal connectivity  
Mean nodal strength, estimated value (bootstrap-based 95% CI), p-
value 
 
Estimated 
change  
6.755 (0.501 to 12.756), 
p=0.02 
2.901 (0.213 to 6.936), 
p=0.04 
0.40 
Mean clustering coefficient, estimated value (bootstrap-based 95% 
CI), p-value 
   
Estimated 
change  
0.093 (0.007 to 0.184),  
p=0.03 
0.009 (-0.029 to 0.06), 
p=0.80 
0.20 
 
2.  Measures of nodal distance 
 
Mean shortest path, estimated value (bootstrap-based 95% CI), p-
value 
 
Estimated 
change  
-0.548 (-0.843 to -0.179), 
p<0.001 
-0.383 (-0.661 to -0.163), 
p<0.001 
0.60 
Global efficiency, estimated value (bootstrap-based 95% CI), p-
value 
 
Estimated 
change  
0.079 (0.010 to 0.147),  
p=0.02 
-0.003 (-0.039 to 0.044), 
p=0.90 
0.06 
Mean local efficiency, estimated value (bootstrap-based 95% CI), p-
value 
 
Estimated 
change  
0.089 (0.008 to 0.172),  
p=0.02 
0.0054 (-0.0320 to 
0.0582), p=0.9 
0.10 
 
3.  Measures of network organisation 
 
Modularity coefficient (bootstrap-based 95% CI), p-value  
Estimated 
change  
-0.008 (-0.037 to 0.020),  
p=0.7 
0.019 (-0.006 to 0.038), 
p=0.15 
0.20 
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Figure legends 
 
Figure 1. Network parameters at baseline in all PPMS patients and HCs 
 
Figure 1. (Figure legend) This figure shows the point estimates for the baseline values 
of network parameters (thick vertical lines, in red for PPMS and black for HCs) and the 
bootstrap-based 95% CIs for those values, for all PPMS patients and HCs (thin vertical 
lines, in red for PPMS and black for HCs). The blue-purple histograms reflect the 
bootstrap distribution in PPMS patients, whereas the green histograms reflect the 
bootstrap distribution in HCs. Please look at the main text for more details. 
Abbreviations: CI: Confidence Interval; HCs: healthy controls; PPMS: primary 
progressive multiple sclerosis.     
 29 
Figure 2. Five-year changes in network parameters in all PPMS patients and HCs 
 
Figure 2. (Figure legend) This figure shows the point estimates for the five-year 
changes in network parameters (thick vertical lines, in red for PPMS and black for HCs) 
and the bootstrap-based 95% CIs for those changes, for all PPMS patients and HCs 
(thin vertical lines, in red for PPMS and black for HCs). The blue-purple histograms 
reflect the bootstrap distribution in PPMS patients, whereas the green histograms reflect 
the bootstrap distribution in HCs. Please look at the main text for more details. 
Abbreviations: CI: Confidence Interval; HCs: healthy controls; PPMS: primary 
progressive multiple sclerosis.    
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Figure 3. Five-year changes in clustering coefficient and local efficiency in all 
groups 
 
Figure 3. (Figure legend) This figure shows the five-year changes in clustering 
coefficient and local efficiency for all four networks. A: all-PPMS network; B: HC 
network; C: fast-PPMS network; D: slow-PPMS network. As can be seen, all changes 
ranged from -0.11 to 0.11. Patients with fast clinical progression showed the greatest 
(positive) change in both clustering coefficient and local efficiency. Abbreviations: 
HCs: healthy controls; PPMS: primary progressive multiple sclerosis.    
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Figure 4. Network parameters at baseline in PPMS patients with fast and slow 
progression  
 
Figure 4. (Figure legend) This figure shows the point estimates for the baseline values 
of network parameters (thick vertical lines, in red and black, for patients with fast and 
slow progression, respectively) and the bootstrap-based 95% CIs for those values, for 
PPMS patients with fast and slow progression (thin vertical lines, in red and black, for 
patients with fast and slow progression, respectively). The blue-purple histograms 
reflect the bootstrap distribution in PPMS patients, whereas the green histograms reflect 
the bootstrap distribution in HCs. Please look at the main text for more details. 
Abbreviations: CI: Confidence Interval; PPMS: primary progressive multiple sclerosis.    
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Figure 5. Five-year changes in network parameters in PPMS patients with fast 
and slow progression  
 
Figure 5. (Figure legend) This figure shows the point estimates for the five-year 
changes in network parameters (thick vertical lines, in red and black, for patients with 
fast and slow progression, respectively) and the bootstrap-based 95% CIs for those 
changes, for PPMS patients with fast and slow progression (thin vertical lines, in red 
and black, for patients with fast and slow progression, respectively). The blue-purple 
histograms reflect the bootstrap distribution in PPMS patients, whereas the green 
histograms reflect the bootstrap distribution in HCs. Please look at the main text for 
more details. Abbreviations: CI: Confidence Interval; PPMS: primary progressive 
multiple sclerosis. 
 
 
